

YOU CAN HANDLE IT with Innohep.[®]

Thrombosis is a leading cause of death in patients with cancer.¹

In cancer, DVT/PE isn't the only factor.

- Advanced age, renal function, and weight extremes must be considered.²⁻⁴

Not all LMWHs are the same.

- Safety data were collected in over 800 patients with cancer in clinical trials with Innohep[®] (tinzaparin sodium injection).⁵

Innohep[®] is made to handle complicated patients.

- One dose. One shot. Once a day.⁶

Contact your Pharmion representative to learn more about Innohep[®].

1 (866) PHARMION or www.innohep.com


Please see brief summary of Full Prescribing Information on adjacent pages.

UFH=Unfractionated Heparin

* The 95% confidence interval for the total thromboembolic event rate difference (4.0%) was 0.07%, 8.07%.⁶

† The 95% confidence interval for the mortality difference (5.0%) was 0.16%, 9.76%.⁶

Thromboembolic event and mortality rates with Innohep[®] vs. UFH



90-day cumulative thromboembolic event rate in total patient population⁶

90-day cumulative mortality rate in total patient population⁶

■ Innohep[®] (n=216⁶; 47 with cancer⁵)
■ UFH (n=219⁶; 50 with cancer⁵)

The 90-day cumulative thromboembolic event rate with Innohep[®] was not significantly different than the rate with UFH.⁶

Innohep[®]

(tinzaparin sodium injection)

BECAUSE DVT/PE ISN'T THE ONLY FACTOR.

hematuria (1.0%), and thrombocytopenia (1.0%). Innohep[®] cannot be used interchangeably (unit for unit) with heparin or other LMWHs as they differ in manufacturing process, molecular weight distribution, anti-Xa and anti-IIa activities, units, and dosage. Each of these medications has its own instructions for use.

References: 1. Donati MB. Cancer and thrombosis. *Haemostasis*. 1994;24(2):128-131. 2. Questions and answers: annual report to the nation on the status of cancer 1973-1999, featuring implications of age and aging on the U.S. cancer burden. National Cancer Institute. 2002. Available at: <http://newscenter.cancer.gov/pressreleases/2002reportq&a.html>. Accessed August 28, 2002. 3. Table 57. Number of selected reported chronic conditions per 1,000 persons, by age: United States, 1996-Con. CDC. National Center for Health Statistics. Available at: <http://www.cdc.gov/nchs/fastats/kidbladd.htm>. Accessed August 28, 2002. 4. Souba WW. Nutritional support. Clinical manifestations of cancer cachexia. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. *Cancer. Principles & Practice of Oncology*. 5th ed. New York, NY: Lippincott-Raven; 1996:2841-2842. 5. Data on file, Pharmion Corporation. 6. Innohep[®] [prescribing information]. Boulder, Colo: Pharmion Corporation; June 2002.

"Priority Medicine. In Practice." is a trademark of Pharmion Corporation.

Innohep[®] is a registered trademark of LEO Pharma.

© 2002 Pharmion Corporation. All rights reserved.

2002066 October 2002 Printed in USA

PHARMION
Priority Medicine. In Practice.™